Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma
February 19, 2008
Are Gemcitabine and Docetaxel active as a first-line regiment for metastatic leiomyosarcoma?
Gemcitabine 900 mg/m2 IV days 1-8
Docetaxel 100 mg/m2 IV day 8
Filgastrim 150 ug/m2 SQ day 9-15 or Pegfilgrastrim 6mg SQ day 9 or 10
q3 wks
ORR
Advanced, unresectable uterine leiomyosarcoma
prior chemotherapy
Gem/Doce:
ORR 35.8%
Duration of Response: 6 months
Median PFS: 4.4 mos
Median OS: 16+ mos
G3/4 Neutropenia: 17%
G3 Anemia: 24%
G3 Thrombocytopenia: 14.5%
Gemcitabine with Docetaxel has high objective response rates as first-line therapy in metastatic uterine leiomyosarcoma